Q3 Net Loss Halves to $7.4M as Arcturus Guides Cash Runway to 2028
ARCT sits 70% above its 52-week low of $5.5.
Summary
Arcturus cut its third-quarter net loss to $7.4 million from $13.4 million a year earlier, or 26 cents a share, helped by a $12.0 million termination payment from CSL Seqirus that lifted revenue to $18.3 million from $17.2 million. R&D spending fell to $17.0 million from $23.3 million as the company wound down LUNAR-COVID and BARDA work and concentrated on its rare-disease pipeline. Cash stood at $184.8 million at quarter-end, down $46.1 million this year, and management says that funds operations through year-end 2028. The pipeline update follows the September 8-K with encouraging ARCT-810 Phase 2 interim data and the LUNAR 2.0 platform, which showed 38-fold greater potency than the key ARCT-810 lipid in non-human primates. ARCT-032 cystic fibrosis Phase 2 full data are slated for Q2 2027, with a Phase 3 go-decision from Thermo Fisher expected before then, and ARCT-2601 OTC deficiency dosing starts Q1 2027 with top-line data in H2 2027. The myNEO acquisition has closed, and KOSTAIVE marketing authorizations in the EU and UK have transferred to Arcturus ahead of a 2027 launch.
At the time of this announcement, ARCT was trading at $9.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $265.5M. The 52-week trading range was $5.50 to $17.96. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: BusinessWire.